Lpath hit another round of bad luck when its lipid-targeted eye drug failed to show a statistically significant benefit in a Phase II study of patients with wet age-related macular degeneration, forcing the company to cut costs and employees.
The San Diego biotech announced 20 May that iSONEP failed to improve visual clarity for the 158 wet AMD patients...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?